A carregar...
Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial
AIMS: The AleCardio trial aimed to characterize the efficacy and safety of peroxisome proliferator‐activated receptor‐αγ agonist aleglitazar in patients with type 2 diabetes mellitus and acute coronary syndrome. The trial terminated early because of futility and safety signals. We evaluated whether...
Na minha lista:
| Publicado no: | Diabetes Obes Metab |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Blackwell Publishing Ltd
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6916612/ https://ncbi.nlm.nih.gov/pubmed/31468659 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13862 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|